SCHEMBL498127

SCHEMBL498127

COc1ccc(C=O)cc1OCC1CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
TSHR P16473 1/20 0.62
PDE4B Q07343 11/20 0.62
FDPS P14324 1/20 0.58
PDE4A P27815 1/20 0.57
PDE4C Q08493 1/20 0.57
PDE4D Q08499 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
AOX1 Q06278 1/20 0.49
TRIM24 O15164 1/20 0.49
HPGD P15428 1/20 0.49
ALDH5A1 P51649 1/20 0.49
ABAT P80404 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
PDCD1 Q15116 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30352601 1.00 ALDH1A1 (0.62) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL6584890 0.95 ALDH1A1 (0.60) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL6584909 0.94 ALDH1A1 (0.58) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL637014 0.94 FDPS (0.67) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL9733843 0.93 ALDH1A1 (0.57) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL6585016 0.88 FDPS (0.62) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL2843045 0.87 FDPS (0.61) ALDH1A1TSHRPDE4BFDPSSMN1; SMN2
SCHEMBL13232716 0.85 DRD2 (0.47) ALDH1A1TSHRPDE4BFDPSPDE4A
SCHEMBL31619155 0.85 PDE4B (0.58) PDE4BPDE4APDE4CPDE4D
SCHEMBL20748342 0.84 PDE4B (0.46) ALDH1A1TSHRPDE4BFDPSPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136683-A Catechol ether compound, pharmaceutical composition and application thereof 中国药科大学 2025-06-13 CN disclosed
EP-3777979-B1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) 2024-01-17 EP disclosed
EP-3777979-B1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) 2024-01-17 EP disclosed
CN-110407741-B Anti-inflammatory compound and preparation and application thereof 启元生物(杭州)有限公司 2023-03-21 CN disclosed
US-11440886-B2 Anti-inflammatory compound, and preparation and use thereof E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (CN) 2022-09-13 US disclosed
EP-3777979-A1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF Vivavision Biotech, Inc. (CN) 2021-02-17 EP disclosed
EP-3777979-A1 ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF Vivavision Biotech, Inc. (CN) 2021-02-17 EP disclosed
US-20200377460-A1 ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH, INC. (CN) 2020-12-03 US disclosed
US-20200377460-A1 ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF VIVAVISION BIOTECH, INC. (CN) 2020-12-03 US disclosed
EP-2283017-B1 FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2015-08-05 EP disclosed
US-5449686-A Compounds useful for treating allergic or inflammatory diseases SMITHKLINE BEECHAM CORPORATION (US) 1995-09-12 US disclosed
WO-1995020578-A1 SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS RHONE-POULENC RORER LIMITED (GB) 1995-08-03 WO disclosed
EP-0652868-A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF RHONE-POULENC RORER LIMITED (GB) 1995-05-17 EP disclosed
EP-0636025-A4 COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES. 1995-02-22 EP disclosed
EP-0633775-A4 COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND FOR INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR. 1995-02-22 EP disclosed
EP-0636025-A1 COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1995-02-01 EP disclosed
EP-0633775-A1 COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND FOR INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR SMITHKLINE BEECHAM CORPORATION (US) 1995-01-18 EP disclosed
WO-1994002465-A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF RHONE-POULENC RORER LIMITED (GB) 1994-02-03 WO disclosed
WO-1993019750-A1 COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1993-10-14 WO disclosed
WO-1993019748-A1 COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES AND FOR INHIBITING PRODUCTION OF TUMOR NECROSIS FACTOR SMITHKLINE BEECHAM CORPORATION (US) 1993-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11440886-B2 Anti-inflammatory compound, and preparation and use thereof PDE4B, PDE4A, PDE7A ALDH1A1 1382/4885TSHR 4371/4885PDE4B 1/4885
US-20200377460-A1 ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF PDE4B, PDE4A, PDE7A ALDH1A1 1382/4885TSHR 4371/4885PDE4B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.